DDInter1397 DDInter1693
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions.
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Digitoxin
Digitoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) downregulates {v} (Gene) RRP8
RRP8 {u} (Gene) is upregulated by {v} (Compound) Digitoxin
Digitoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) upregulates {v} (Gene) MAP1LC3B
MAP1LC3B {u} (Gene) is upregulated by {v} (Compound) Digitoxin
Digitoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) downregulates {v} (Gene) RRP8
RRP8 {u} (Gene) is upregulated by {v} (Compound) Cilostazol
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) upregulates {v} (Gene) MAP1LC3B
MAP1LC3B {u} (Gene) is upregulated by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) upregulates {v} (Gene) MAP1LC3B
MAP1LC3B {u} (Gene) is upregulated by {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) upregulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) downregulates {v} (Gene) CDC25A
CDC25A {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Paroxetine {u} (Compound) downregulates {v} (Gene) CDC25A
CDC25A {u} (Gene) is downregulated by {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Sodium sulfate
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Paroxetine (Compound) downregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Paroxetine (Compound) upregulates MAP1LC3B (Gene) and MAP1LC3B (Gene) is upregulated by Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Paroxetine (Compound) downregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Cilostazol (Compound) and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Paroxetine (Compound) upregulates MAP1LC3B (Gene) and MAP1LC3B (Gene) is upregulated by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Paroxetine (Compound) upregulates MAP1LC3B (Gene) and MAP1LC3B (Gene) is upregulated by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Sodium sulfate
Paroxetine (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Paroxetine (Compound) downregulates CDC25A (Gene) and CDC25A (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Paroxetine (Compound) downregulates CDC25A (Gene) and CDC25A (Gene) is downregulated by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Sodium sulfate